The most significant genetic predictors of drug response

Organ or systems involved

Associated gene/allele

Drug/drug response pathway

Blood Red blood cells Neutrophils Platelets Coagulation

G6PD TMPT*2 UGT1A1*28 CYP2C19*2 CYP2C9*2, *3, VKORC1

Primaquine and others Azathioprine/6MP-induced neutropenia Irinotecan-induced neutropenia Stent thrombus Warfarin dose-requirement

Brain and peripheral nervous system CNS depression Anaesthesia Peripheral nerves

CYP2D6*N Butyrylcholinesterase NAT-2

Codeine-related sedation and respiratory depression Prolonged apnea Isoniazid-induced peripheral neuropathy

Drug hypersensitivity

HLA-B*5701 HLA-B*1502 HLA-A*3101 HLA-B*5801

Abacavir sensitivity Carbamazepine-induced Stevens Johnson syndrome (in some Asian groups)

Carbamazepine-induced hypersensitivity in Caucasians and Japanese Allopurinol-induced serious cutaneous reactions

Drug-induced liver injury

HLA-B*5701 HLA-DRB1*1501-DQB1*0602 HLA-DRB1*1501-DQB1*0602 HLA-DRB1*07-DQA1*02 HLA-DQA1*0201

Flucloxacillin Co-amoxiclav Lumiracoxib Ximelagatran Lapatinib

Infections HIV-1 infection Hepatitis C infection

CCR5 IL28B

Maraviroc efficacy Interferon-alpha efficacy

Malignancy Breast cancer Chronic myeloid leukemia Colon cancer GI stromal cancer Lung cancer Malignant melanoma

CYP2D6 BCR-ABL KRAS c-kit EGFR EML4-ALK BRAF V600E

Response to Tamoxifen Imatinib and other tyrosine kinase inhibitors Cetuximab efficacy Imatinib efficacy Gefitinib efficacy Crizotinib efficacy Vemurafenib efficacy

Muscle General anaesthetics Statins

Ryanodine receptor SLCO1B1

Malignant hyperthermia Myopathies/rhabdomyolysis